The acquisition gives the pharmaceutical company access to Omniose’s proprietary bioconjugation platform, which is designed to simplify the development and production of bacterial conjugate vaccines.
AstraZeneca plans to reinvest most of the savings in research and development, although the programme is expected to incur up to US$2 billion in one-time restructuring costs over three years.
The collaboration will assess MILTON, AstraZeneca’s AI-powered disease prediction platform, for use in UAE populations, focusing initially on type 2 diabetes and cardiovascular disease.
Under the agreement, AstraZeneca will pay US$40 million upfront, with an additional US$1.46 billion available in development and commercial milestone payments.
Located in Kendall Square, a major biotechnology and life sciences hub, the new centre will operate alongside AstraZeneca’s genomic medicine facility at 100 Binney Street.
Under the partnership, AstraZeneca and UNICEF will train and support 5,000 young people to take part in NCD prevention activities and youth-led health initiatives.
The companies have also signed a non-binding MoU covering a broader global programme to evaluate ivonescimab in combination with additional AstraZeneca oncology therapies.
The new venture will initially manufacture biologic drug substances that the two companies mutually select for global markets.
Both programmes will combine SOPHiA GENETICS’ decentralised clinical trial assay capabilities with AstraZeneca’s oncology therapies.
The new collaboration centres on CSPC’s small interfering RNA (siRNA) drug discovery platform and its proprietary delivery technology, which is designed to transport therapies beyond the liver.